BioAge Labs (BIOA) director granted 22,000 stock options at $15.48 strike

Rhea-AI Filing Summary

BioAge Labs, Inc. director Michael H. Davidson received a grant of stock options covering 22,000 shares of common stock. These options have an exercise price of $15.48 per share and expire on June 9, 2036. The entire award will vest on the earlier of the company’s next annual stockholder meeting or the one-year anniversary of the grant date, as long as he continues serving the company through that vesting date. Following this grant, Davidson holds 22,000 stock options directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Davidson Michael H.

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	22,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 22,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 22,000 options Exercise price: $15.48 per share Expiration date: June 9, 2036 +1 more

4 metrics

Options granted 22,000 options Stock Option (Right to Buy) grant to director

Exercise price $15.48 per share Strike price for option grant

Expiration date June 9, 2036 Option term end date

Post-grant derivative holdings 22,000 options Total stock options following transaction

Key Terms

Stock Option (Right to Buy), exercise price, expiration date, vest, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

exercise price financial

"conversion_or_exercise_price: "15.4800""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: "2036-06-09T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vest financial

"The entire option award shall vest on the earlier of"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

grant date financial

"the one year anniversary of the grant date"

The grant date is the day a company formally gives an employee or contractor the right to receive stock-based compensation, such as stock options or restricted shares. It matters to investors because it fixes key terms—like the price, the start of the ownership clock, and when the award will affect the company’s financial statements and share count—so it can influence dilution, reported expenses, and potential future selling pressure.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Davidson Michael H.

(Last) (First) (Middle)

C/O BIOAGE LABS, INC.

5885 HOLLIS STREET, SUITE 370

(Street)

EMERYVILLE CALIFORNIA 94608

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BioAge Labs, Inc. [ BIOA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$15.48	06/10/2026		A		22,000		(1)	06/09/2036	Common Stock	22,000	$0	22,000	D

Explanation of Responses:

1. The entire option award shall vest on the earlier of: (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the one year anniversary of the grant date, subject to the reporting person's continued service to the Issuer on the applicable vesting date.

	/s/ Dov A. Goldstein as attorney-in-fact	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did BioAge Labs (BIOA) director Michael H. Davidson report on this Form 4?

Michael H. Davidson reported receiving a grant of stock options for 22,000 shares of BioAge Labs common stock. The options were awarded as compensation and give him the right to buy shares at a fixed exercise price in the future, subject to vesting.

How many BioAge Labs (BIOA) stock options were granted to Michael H. Davidson?

He was granted stock options covering 22,000 shares of BioAge Labs common stock. This entire grant is currently unexercised and represents his total derivative holdings reported after the transaction, according to the filing’s post-transaction share balance.

What is the exercise price and expiration date of Michael H. Davidson’s BIOA options?

The stock options have an exercise price of $15.48 per share and expire on June 9, 2036. This means he can choose to buy shares at $15.48 any time before that expiration date, once the options vest.

When do Michael H. Davidson’s BioAge Labs (BIOA) options vest?

The entire option award vests on the earlier of the next annual meeting of BioAge Labs stockholders or the one-year anniversary of the grant date. Vesting is contingent on Davidson’s continued service to the company through the applicable vesting date.

Is Michael H. Davidson’s BIOA option grant an open-market purchase or a compensation award?

The transaction is a compensation-related award, not an open-market purchase. It is coded as a grant or award acquisition, with zero purchase price at grant and a set exercise price of $15.48 per share for future potential exercises.

How is Michael H. Davidson’s ownership in BioAge Labs (BIOA) classified after this option grant?

After the grant, Davidson directly holds 22,000 stock options linked to BioAge Labs common stock. The filing classifies this as direct ownership, meaning the options are held in his own name rather than through an intermediary entity or trust.